Multiple Myeloma Global Market Report 2025

Description

Multiple myeloma is a form of cancer originating in a type of white blood cell known as a plasma cell. In this condition, cancerous plasma cells accumulate in the bone marrow, displacing healthy blood cells. The cancer cells produce abnormal proteins that can lead to complications rather than contributing to the production of beneficial antibodies.

The primary treatments for multiple myeloma encompass various approaches such as medications, radiation therapy, stem cell transplant, and others. Medications, in this context, refer to dosage forms containing both potentially inert substances and one or more active chemicals aimed at managing the disease. To diagnose active multiple myeloma and smoldering multiple myeloma, healthcare professionals employ blood tests, bone marrow biopsy, urine tests, and imaging tests. Treatment modalities can be administered through different channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels.

The multiple myeloma research report is one of a series of new reports from The Business Research Company that provides multiple myeloma market statistics, including the multiple myeloma industry's global market size, regional shares, competitors with multiple myeloma market share, detailed multiple myeloma market segments, market trends and opportunities, and any further data you may need to thrive in the multiple myeloma industry. This multiple myeloma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The multiple myeloma market size has grown strongly in recent years. It will grow from $26.07 billion in 2024 to $28.15 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to diagnostic improvements, the introduction of stem cell transplantation, access to high-quality medical care, precision medicine approaches, and patient-centric care models

The multiple myeloma market size is expected to see strong growth in the next few years. It will grow to $38.39 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to health technology integration, adoption of telemedicine services, personalized vaccine therapies, and digital health platforms for patient education. Major trends in the forecast period include advancements in targeted therapies, novel drug development, immunotherapy advancements, novel biomarker development, and integration of artificial intelligence.

The anticipated growth in the multiple myeloma market is expected to be driven by the increasing prevalence of this form of cancer. Multiple myeloma, which originates in plasma cells, is influenced by factors such as age, genetics, obesity, and radiation exposure. The rise in the number of cases is evident, as reported by the American Cancer Society, with new cases increasing from 34,470 in 2022 to 35,730 in 2023. This escalation in prevalence underscores the imperative for advancements in multiple myeloma treatments, thereby contributing to the growth of the market.

The growth in healthcare expenditures is poised to propel the multiple myeloma market forward. Healthcare expenditures, representing the total monetary outlay on healthcare goods and services within a defined period, play a significant role in the treatment and management of multiple myeloma. These expenditures cover various aspects, including therapies, medications, hospitalization, and supportive care. As indicated by the Canadian Institute for Health Information (CIHI) in November 2022, the forecasted rise in total health spending in Canada from $328 billion in 2021 to $331 billion in 2022 reflects the increasing financial commitment to healthcare. This upward trend in healthcare expenditures is expected to drive advancements in multiple myeloma treatment options and contribute to the overall growth of the market.

Product innovation stands out as a prominent trend in the multiple myeloma market, with major companies actively engaged in developing innovative therapies to maintain their competitive positions. In October 2022, Janssen Pharmaceutical Companies of Johnson & Johnson achieved FDA approval for TECVAYLI (teclistamab-cqyv), the first bispecific T-cell engager antibody. This drug is intended for the treatment of adult patients with multiple myeloma who have undergone at least four prior lines of therapy, including various drugs. TECVAYLI targets the B-cell maturation antigen (BCMA) expressed on certain B-lineage cells, as well as the CD3 receptor found on T-cells and multiple myeloma cells.

Major players in the multiple myeloma market are also focusing on the development of novel therapies such as CAR T-cell therapy (Chimeric Antigen Receptor T-cell therapy) to gain a competitive advantage. In December 2023, Bristol Myers Squibb received approval for Abecma, the first CAR T-cell therapy for earlier use in patients with relapsed or refractory multiple myeloma who have undergone at least two prior therapies. Abecma, a B-cell maturation antigen (BCMA)-directed CAR T-cell immunotherapy, demonstrated significant improvements in median progression-free survival (mPFS) and overall response rate (ORR) based on the interim analysis of the KarMMa-3 Phase 3 study.

In February 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for an undisclosed amount. This acquisition highlights AstraZeneca's strategic effort to bolster its presence in immuno-oncology and cellular therapies by leveraging Gracell's cutting-edge platform and expertise. Gracell Biotechnologies Inc., a China-based company, specializes in the clinical development of FasTCAR-T GC012F for the treatment of multiple myeloma.

Major companies operating in the multiple myeloma market include Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Janssen Global Services LLC, Celgene Corporation, Mylan N.V., Biogen Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., CRISPR Therapeutics AG, Karyopharm Therapeutics Inc., Fate Therapeutics Inc., Atara Biotherapeutics Inc., Allogene Therapeutics Inc., C4 Therapeutics Inc., Adaptimmune Therapeutics plc, Precision Biosciences Inc.

North America was the largest region in the multiple myeloma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple myeloma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the multiple myeloma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multiple myeloma market consists of revenues earned by entities by providing services such as treatment planning, supportive care, and diagnostic testing such as computerized tomography (CT scans), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The multiple myeloma market also includes sales of thalidomide, bortezomib, and daratumumab which are used in providing multiple myeloma services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multiple Myeloma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multiple myeloma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multiple myeloma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multiple myeloma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment: Medications; Radiation Therapy; Stem Cell Transplant; Other Treatments
2) By Diagnosis: Blood Tests; Bone Marrow Biopsy; Urine Tests; Imaging Tests
3) By Disease Type: Active Multiple Myeloma; Smoldering Multiple Myeloma
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Channels
Subsegments:
1) By Medications: Immunomodulatory Drugs (IMiDs); Proteasome Inhibitors; Monoclonal Antibodies; Corticosteroids; Chemotherapy Agents
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Radioisotope Therapy
3) By Stem Cell Transplant: Autologous Stem Cell Transplant (ASCT); Allogeneic Stem Cell Transplant
4) By Other Treatments: Supportive Care; Clinical Trials And Experimental Therapies
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r25128

1. Executive Summary

2. Multiple Myeloma Market Characteristics

3. Multiple Myeloma Market Trends And Strategies

4. Multiple Myeloma Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Multiple Myeloma Growth Analysis And Strategic Analysis Framework

5.1. Global Multiple Myeloma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Multiple Myeloma Market Growth Rate Analysis
5.4. Global Multiple Myeloma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Multiple Myeloma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Multiple Myeloma Total Addressable Market (TAM)

6. Multiple Myeloma Market Segmentation

6.1. Global Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medications
Radiation Therapy
Stem Cell Transplant
Other Treatments
6.2. Global Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Blood Tests
Bone Marrow Biopsy
Urine Tests
Imaging Tests
6.3. Global Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Active Multiple Myeloma
Smoldering Multiple Myeloma
6.4. Global Multiple Myeloma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Other Channels
6.5. Global Multiple Myeloma Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunomodulatory Drugs (IMiDs)
Proteasome Inhibitors
Monoclonal Antibodies
Corticosteroids
Chemotherapy Agents
6.6. Global Multiple Myeloma Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
External Beam Radiation Therapy (EBRT)
Radioisotope Therapy
6.7. Global Multiple Myeloma Market, Sub-Segmentation Of Stem Cell Transplant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Autologous Stem Cell Transplant (ASCT)
Allogeneic Stem Cell Transplant
6.8. Global Multiple Myeloma Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Supportive Care
Clinical Trials And Experimental Therapies

7. Multiple Myeloma Market Regional And Country Analysis

7.1. Global Multiple Myeloma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Multiple Myeloma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Multiple Myeloma Market

8.1. Asia-Pacific Multiple Myeloma Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Multiple Myeloma Market

9.1. China Multiple Myeloma Market Overview
9.2. China Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Multiple Myeloma Market

10.1. India Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Multiple Myeloma Market

11.1. Japan Multiple Myeloma Market Overview
11.2. Japan Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Multiple Myeloma Market

12.1. Australia Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Multiple Myeloma Market

13.1. Indonesia Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Multiple Myeloma Market

14.1. South Korea Multiple Myeloma Market Overview
14.2. South Korea Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Multiple Myeloma Market

15.1. Western Europe Multiple Myeloma Market Overview
15.2. Western Europe Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Multiple Myeloma Market

16.1. UK Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Multiple Myeloma Market

17.1. Germany Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Multiple Myeloma Market

18.1. France Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Multiple Myeloma Market

19.1. Italy Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Multiple Myeloma Market

20.1. Spain Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Multiple Myeloma Market

21.1. Eastern Europe Multiple Myeloma Market Overview
21.2. Eastern Europe Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Multiple Myeloma Market

22.1. Russia Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Multiple Myeloma Market

23.1. North America Multiple Myeloma Market Overview
23.2. North America Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Multiple Myeloma Market

24.1. USA Multiple Myeloma Market Overview
24.2. USA Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Multiple Myeloma Market

25.1. Canada Multiple Myeloma Market Overview
25.2. Canada Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Multiple Myeloma Market

26.1. South America Multiple Myeloma Market Overview
26.2. South America Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Multiple Myeloma Market

27.1. Brazil Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Multiple Myeloma Market

28.1. Middle East Multiple Myeloma Market Overview
28.2. Middle East Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Multiple Myeloma Market

29.1. Africa Multiple Myeloma Market Overview
29.2. Africa Multiple Myeloma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Multiple Myeloma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Multiple Myeloma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Multiple Myeloma Market Competitive Landscape And Company Profiles

30.1. Multiple Myeloma Market Competitive Landscape
30.2. Multiple Myeloma Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Multiple Myeloma Market Other Major And Innovative Companies

31.1. Bayer AG
31.2. Novartis AG
31.3. Sanofi S.A.
31.4. Bristol-Myers Squibb Company
31.5. AstraZeneca plc
31.6. Abbott Laboratories
31.7. GlaxoSmithKline PLC
31.8. Takeda Pharmaceutical Company Limited
31.9. Eli Lilly and Company
31.10. Boehringer Ingelheim International GmbH
31.11. Amgen Inc.
31.12. Janssen Global Services LLC
31.13. Celgene Corporation
31.14. Mylan N.V.
31.15. Biogen Inc.

32. Global Multiple Myeloma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Multiple Myeloma Market

34. Recent Developments In The Multiple Myeloma Market

35. Multiple Myeloma Market High Potential Countries, Segments and Strategies

35.1 Multiple Myeloma Market In 2029 - Countries Offering Most New Opportunities
35.2 Multiple Myeloma Market In 2029 - Segments Offering Most New Opportunities
35.3 Multiple Myeloma Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer